P

Patricia A. Escobar

Merck & Co., Inc., Rahway, NJ, USA (United States)

ORCID: 0000-0001-9703-6330

37 papers and 1.6k citations.

PubIndex Score51Top 49% · mid-careerHow it's scored

37Publications

1.6kTotal Citations

First publication: 2006

Top publicationsby citations

Application of the adverse outcome pathway framework to genotoxic modes of action

Jennifer C. Sasaki, Maik Schuler, Albert J. Fornace et al.|Environmental and Molecular Mutagenesis|2019

Cited by 56

Comparison of the transgenic rodent mutation assay, error corrected next generation duplex sequencing, and the alkaline comet assay to detect dose-related mutations following exposure to N-nitrosodiethylamine

Joel P. Bercu, Maik Schuler, Shaofei Zhang et al.|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2023

Cited by 34

Next Generation Sequencing Workshop at the Royal Society of Medicine (London, May 2022): how genomics is on the path to modernizing genetic toxicology

Anthony M Lynch, A. E. Ashford, Thalita B. Zanoni et al.|Mutagenesis|2023

Cited by 7

Ames concordance with the in vivo transgenic rodent (TGR) gene mutation assay for NDSRIs and relative in vivo TGR potency with nitrosamines with robust dose-response carcinogenicity data

Robert A. Jolly, Raechel Puglisi, Alejandra Trejo-Martin et al.|Regulatory Toxicology and Pharmacology|2026

Cited by 3

Indexing the rest of 37 publications…